Patients enrolled in the PIONEER 2 [15], PIONEER 3 [16], SUSTAIN 2 [17], and SUSTAIN 8 [18] trials had type 2 diabetes that was uncontrolled by metformin (with or without sulfonylurea) and were treated with an additional oral/subcutaneous GLP-1RA (semaglutide), oral SGLT-2i (empagliflozin/canagliflozin), or oral DDP-4i (sitagliptin)
This discrepancy between adverse event reporting data and actual incidence data reinforces the limitations of FAERS as a signal detection tool rather than a risk quantification tool
Those suffering from Type 1 Diabetes are not to use Semaglutide under any circumstances
Why Retatrutide is Exciting : Triple Mechanism = Broader Impact: Targets fat loss, insulin sensitivity, and energy balance simultaneously Once-Weekly Dosing: High compliance, low friction Backed by Data: Clinically validated, outperforming single and dual agonists in key metrics Ideal for Advanced Protocols: Perfect for those looking for the best potential results Outperforms Semaglutide & Tirzepatide for total weight lost in trials Available in Canada with fast domestic shipping Most common side effects: Nausea, diarrhea & constipation Side effects are dose dependent and typically subside the longer the drug is used You can check out the full guide on managing Retatrutide side effects by clicking on the link
